Research map: GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape

Back to the article

Papers in this map

  1. Health Effects of Overweight and Obesity in 195 Countries over 25 Years · The GBD 2015 Obesity Collaborators · 2017 · 8131 citations · Cited by this paper
  2. Prospective multicenter evaluation of glycemic and patient-reported outcomes following transition to a next-generation continuous glucose monitoring system in users of advanced hybrid closed-loop technology · 2026 · Related
  3. Once-Weekly Semaglutide in Adults with Overweight or Obesity · John P.H. Wilding · 2021 · 5054 citations · Cited by this paper
  4. Metformin and bone metabolism: unraveling their direct and indirect effects · 2025 · Related
  5. Tirzepatide Once Weekly for the Treatment of Obesity · Ania M. Jastreboff · 2022 · 3661 citations · Cited by this paper
  6. GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications · 2025 · Related
  7. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes · A. Michael Lincoff · 2023 · 3058 citations · Cited by this paper
  8. Contribution of DNA methylation predicted leptin to all-cause, cancer, and cardiovascular mortality among US adults aged 50 years and older: findings from NHANES 1999–2002 · 2026 · Related
  9. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults · Nowell H Phelps · 2024 · 2417 citations · Cited by this paper
  10. The effect of concurrent exercise training (Resistance and Interval Running) and mindful self-compassion therapy on heart rate Variability in type 1 diabetes · 2026 · Related
  11. Glucagon-like peptide 1 (GLP-1) · Timo D. Müller · 2019 · 1844 citations · Cited by this paper
  12. Use of serum MKRN3 and DLK1 levels in precocious puberty: association with an MKRN3 pathogenic variant · 2026 · Related
  13. Joint international consensus statement for ending stigma of obesity · Francesco Rubino · 2020 · 1147 citations · Cited by this paper
  14. The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials · 2025 · Related
  15. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials · Robin Christensen · 2007 · 1097 citations · Cited by this paper
  16. A case of immune thrombocytopenia aggravated by therapy for hypercortisolism in adrenocortical carcinoma · 2026 · Related
  17. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension · John P.H. Wilding · 2022 · 1076 citations · Cited by this paper
  18. The role of mycophenolate mofetil in the therapy of thyroid eye disease · 2025 · Related
  19. Anti-obesity drug discovery: advances and challenges · Timo D. Müller · 2021 · 1011 citations · Cited by this paper
  20. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects · W. P. T. James · 2010 · 947 citations · Cited by this paper
  21. NHSR 158. National Health and Nutrition Examination Survey 2017–March 2020 Pre-pandemic Data Files · Stierman Bryan · 2021 · 494 citations · Cited by this paper
  22. Direct medical costs of obesity in the United States and the most populous states · John Cawley · 2021 · 408 citations · Cited by this paper
  23. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial · Donna H. Ryan · 2024 · 346 citations · Cited by this paper
  24. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus · Juan José Gorgojo Martínez · 2022 · 340 citations · Cited by this paper
  25. Mapping the effectiveness and risks of GLP-1 receptor agonists · Yan Xie · 2025 · 289 citations · Cited by this paper
  26. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials · Hon Jen Wong · 2025 · 192 citations · Cited by this paper
  27. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment · Sean Wharton · 2025 · 160 citations · Cited by this paper
  28. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK · Tracey Weiss · 2022 · 152 citations · Cited by this paper
  29. Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial · John M. Sharretts · 2020 · 146 citations · Cited by this paper
  30. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults · Francesca L. Celletti · 2025 · 135 citations · Cited by this paper
  31. Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society · Dariush Mozaffarian · 2025 · 125 citations · Cited by this paper
  32. Effectiveness and safety of drugs for obesity · Kristina Henderson Lewis · 2024 · 65 citations · Cited by this paper
  33. Semaglutide Eligibility Across All Current Indications for US Adults · Ivy Shi · 2024 · 53 citations · Cited by this paper
  34. Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity · Jennifer H. Hwang · 2025 · 41 citations · Cited by this paper
  35. Obesity management: at the forefront against disease stigma and therapeutic inertia · Luca Busetto · 2021 · 38 citations · Cited by this paper
  36. Association of patient characteristics and insurance type with anti‐obesity medications prescribing and fills · Hamlet Gasoyan · 2024 · 38 citations · Cited by this paper
  37. International lack of equity in modern obesity therapy: the critical need for change in health policy · Pia Roser · 2022 · 35 citations · Cited by this paper
  38. Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists · William Timothy Garvey · 2024 · 33 citations · Cited by this paper
  39. Estimating the lives that could be saved by expanded access to weight-loss drugs · Abhishek Pandey · 2024 · 20 citations · Cited by this paper

Source: OpenAlex (CC0)